Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer


  • Amal A. Hussein Laboratory of Clinical Biochemistry, Al-Imamain Al-Kadhimain Medical City, Baghdad, Iraq
  • Rayah S. Baban Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq
  • Alaa G. Hussein Department of Pathology, College of Medicine, Al-Nahrain University, Baghdad, Iraq



benign prostatic hyperplasia, body mass index, free prostatespecific antigen, prostate cancer, prostatespecific antigen, receiver operating characteristic curve


Background: Prostate cancer is one of the most common cancers in men, worldwide. Many markers are suggested for prostate cancer with different specificity and sensitivity.

Objectives: This study is aimed is to examine the possible utility of prostate-specific antigen indices as markers of prostate cancer.

Methods: A case-control study was conducted in the Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq from July 2018 till March 2019, includes 84 subjects divided into three groups: twenty-four patients with prostate cancer (PCA), thirty patients with benign prostatic hyperplasia (BPH) and thirty healthy subjects as a control group were examined in this study. Blood samples from all participants were collected, and before obtaining a prostatic biopsy from patients. Serum prostate-specific antigen (PSA) and free prostate-specific antigen (fPSA) levels were quantified by the ELISA technique.

Results: PSA cut-off value was found to be more than 9.57 ng/ml for PCA patients, values range between 3.17–9.57 ng/ml for BPH patients and cut-off value for control was found to be less than 3.17 ng/ml, while serum (fPSA/PSA)% cut-off value was less than 11.1% for PCA patients, values range between 11.1%—31 % for BPH patients, and cut-off value was greater than 31% for the control group.

Conclusion: There is a highly significant difference in serum PSA levels and (fPSA/PSA)% between the PCA and control groups. Body mass index showed an inverse association with the risk of prostate cancer.


Metrics Loading ...


Download data is not yet available.


Al Baha Barqawi et al. “Observed effect of age and body mass index on total and complexed PSA: Analysis from a national screening program”. Urology 65(4) (2005), pp. 708–712. DOI: 10.1016/j.urology.2004.10.074. DOI:

Athanasios Skarmoutsos et al. “Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target”. Current Urology 12(1) (2018), pp. 13–19. DOI: 10.1159/000447225. DOI:

Bulent Erol et al. “The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: A validation study on a Turkish patient population in different age categories”. The Kaohsiung Journal of Medical Sciences 30(11) (2014), pp. 545–550. DOI: 10.1016/j.kjms.2014.03.008. DOI:

E Eckersberger et al. “Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials”. Rev. Urol 11 (2009), pp. 127–133.

E Spyropoulos. “Considerations Regarding the Predictive Value of PSA Testing , as a Diagnostic Tool for Prostate Cancer in the Current Clinical Practice”. Clin. Oncol 2 (2017), pp. 1–3.

E. Giovannucci et al. “Body Mass Index and Risk of Prostate Cancer in U.S. Health Professionals”. JNCI Journal of the National Cancer Institute 95(16) (2003), pp. 1240–1244. DOI: 10.1093/jnci/djg009. DOI:

Emma H. Allott, Elizabeth M. Masko, and Stephen J. Freedland. “Obesity and Prostate Cancer: Weighing the Evidence”. European Urology 63(5) (2013), pp. 800–809. DOI: 10.1016/j.eururo.2012.11.013. DOI:

Giovanni De Pergola and Franco Silvestris. “Obesity as a Major Risk Factor for Cancer”. Journal of Obesity 2013 (2013), pp. 1–11. DOI: 10.1155/2013/291546. DOI:

H Park et al. “Diagnostic performance of %[-2]proPSA and prostate health index for prostate cancer: Prospective, multi-institutional study”. J. Korean Med. Sci 33 (2018), pp. 94–94. DOI:

J Sritharan. Investigating the Occupational Etiology of Prostate Cancer in Canadian Men. 2018.

J. Shannon et al. “Body mass index, PSA, and prostate cancer risk”. Journal of Clinical Oncology 26(15_suppl) (2008), pp. 5159–5159. DOI: 10.1200/jco.2008.26.15_suppl.5159. DOI:

Jonathan L. Wright, Daniel W. Lin, and Janet L. Stanford. “The effect of demographic and clinical factors on the relationship between BMI and PSA levels”. The Prostate 71(15) (2011), pp. 1631–1637. DOI: 10.1002/pros.21380. DOI:

K Hajian-Tilaki. “Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation”. Casp. J. Intern. Med 4 (2013), pp. 627–635.

L. -B Nan, X. -T Yin, and J. -P Gao. “Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution”. Med. Sci. Monit 25 (2019), pp. 8345–8351. DOI:

LincolnGL Tan et al. “Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1”. Asian Journal of Andrology 19(3) (2017), pp. 286–286. DOI: 10.4103/1008-682x.168687. DOI:

-M Lee, H D Sesso, and R S Paffenbarger. “A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States)”. Cancer Causes Control 12 (2001), pp. 187–193. DOI:

Mariyam Akizhanova et al. “PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis”. Journal of Cancer 8(7) (2017), pp. 1223–1228. DOI: 10.7150/jca.18012. DOI:

Massimo Lazzeri et al. “Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study”. Urologic Oncology: Seminars and Original Investigations 34(9) (2016), 415.e13–415.e19. DOI: 10.1016/j.urolonc.2016.04.003. DOI:

Planning Directorate, Ministry of Health and Environment, Republic of Iraq. 2016.

W. Timothy Garvey et al. “American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity”. Endocrine Practice 22(Supplement 3) (2016), pp. 1–203. DOI: 10.4158/ DOI:

X Filella and L Foj. “Novel biomarkers for prostate cancer detection and prognosis”. Adv. Exp. Med. Biol (2018). Ed. by H. Schatten, pp. 15–39. DOI:



How to Cite

Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. (2020). Baghdad Journal of Biochemistry and Applied Biological Sciences, 1(01), 18-26.